Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Nadia Harbeck(Breast Center), Roberto Hegg, Kevin Punie(KU Leuven), Shilpen Patel, Joohyuk Sohn(Yonsei University), Vidya Maiya, Shigehira Saji(Fukushima Medical University), Kyung Hae Jung(University of Ulsan), Melinda L. Telli(Stanford University), Luciana Molinero, Jane Yuet Ching Hui, Hong Zhang(Anhui Agricultural University), Andreas Koehler(Praxis für Hämatologie und Onkologie), Anh Nguyen Duc(Roche (Switzerland)), Carlos H. Barrios(Eastern Cooperative Oncology Group), Frédérique Penault-Llorca(Inserm), Hiroji Iwata(Aichi Cancer Center), Cristiano Ferrario(Jewish General Hospital), Mario Liste-Hermoso(Roche (Switzerland))
The Lancet
September 20, 2020
10.1016/s0140-6736(20)31953-x
Cited by 1,053

Related Papers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k